Summary
The effects of somatostin analogue, SMS 201–995, on systemic and splanchnic hemodynamics and glucagon secretion were investigated in control and cirrhotic rats induced by thioacetamide administration. Hemodynamics were measured using the radioactive microsphere method. Immunoreactive glucagon (IRG) was determined in the portal vein and femoral artery and the splanchnic output (OP) of IRG was calculated. In control rats, SMS 201–995 induced a decrease of 5.6% in portal venous inflow and a 25.8% decrease in OP of IRG. In cirrhotic rats, SMS 201–995 produced a 14% decrease in portal pressure, a 13.6% decrease in portal venous inflow, and a 57.8% decrease in OP of IRG. In systemic hemodynamics no significant changes were noted following SMS 201–995 administration in the control or cirrhotic rats. The ratio of cirrhotic rats to the controls in the rate of decrease in portal venous inflow was similar to that in the percentage of decrease in OP of IRG. We conclude that SMS 201–995 is useful for the treatment of portal hypertension because of its effect of reducing portal pressure with mild changes in systemic hemodynamics. We suspect that the decrease in portal venous inflow by SMS 201–995 is mainly due to a reduction in the release of glucagon, a vasodilatory gastrointestinal hormone.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Benoit JN, Barrowman JA, Harper SL, et al. Role of humoral factors in the intestinal hyperemia associated with chronic portal hypertension. Am J Physiol 1984;247:G486-G493.
Benoit JN, Zimmerman B, Premen AJ, et al. Role of glucagon in splanchnic hyperemia of chronic portal hypertension. Am J Physiol 1986;251:G674–677.
Silva G, Navasa M, Bosch J, et al. Hemodynamic effects of glucagon in portal hypertension. Hepatology 1990; 11:668–673.
Bauer W, Briner U, Doepfner W, et al. A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31:1133–1140.
Patel YC, Zingg HH, Fitz-Patric D, et al. Somatostatin: some aspects of its physiology and pathophysiology. In: Bloom SR, Polak JM, eds. Gut Hormones. London: Churchill Livingstone, 1981;339–349.
Wahren J, Eriksson LS. The influence of a long-acting somatostatin analogue on splanchnic hemodynamics and metabolism in healthy subjects and patients with liver cirrhosis. Scand J Gastroenterol 1986;21(Suppl 119):103–108.
Eriksson LS, Brundin T, Soderlung C, et al. Haemodynamics effects of a long-acting somatostatin analogue in patients with liver cirrhosis. Scand J Gastroenterol 1987;22:919–925.
Jenkins SA, Baxter JN, Corbett WA, et al. The effects of a somatostatin analogue SMS 201–995 on hepatic hemodynamics in the cirrhotic rat. Br J Surg 1985;72:864–867.
Cerini R, Lee SS, Hadengue A, et al. Circulatory effects of somatostatin analogue in two conscious rat models of portal hypertension. Gastroenterology 1988;94:703–708.
Malik AB, Kaplan JE, Saba TM. Reference sample method for cardiac output and regional blood flow determinations in the rat. J Appl Physiol 1976;40:472–475.
Groszmann RJ, Vorobioff J, Riely E. Splanchnic hemodynamics in portal hypertensive rats: measurement with γ-labeled microspheres. Am J Physiol 1982;242:G156-G160.
Chojkier N, Groszmann RJ. Measurement of portal-systemic shunting in the rat by using γ-labeled microspheres. Am J Physiol 1981;240:G371-G375.
Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology 1981;80:518–525.
Morgan JS, Groszmann RJ. Somatostatin in portal hypertension. Dig Dis Sci 1989;34:(suppl)40s-47s.
Yoneyama K, Hatta Y. Effects of somatostatin and somatostatin analogue on portal and systemic hemodynamics in portal hypertensive dogs. Acta Hepat Jap 1990;31:1305–1314. (in Japanese)
Davies RR, Miller M, Turner SJ, et al. Effects of somatostatin analogue SMS 201–995 in normal man. Clin Endocrinol 1986;24: 665–74.
Kravetz D, Bosch J, Arderiu MT, et al. Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. Am J Physiol 1988;254:G322-G328.
Dashti H, Jeppsson B, Hagerstrand I, et al. Thioacetamideand carbon tetrachloride-induced liver cirrhosis. Eur Surg Res 1989; 21:83–91.
Nuber R, Teutsch HF, Sasse D. Metabolic zonation in thioacetamide-induced liver cirrhosis. Histochemistry 1980;69:277–288.
Sikuler E, Polio J, Groszmann RJ, et al. Glucagon and insulin metabolism in a portal-hypertensive rat model. Am J Physiol 1987;253:G110-G115.
Price BA, Jaffe BM, Zinner MJ. Effect of exogenous somatostatin infusion on gastrointestinal blood flow and hormones in the conscious dog. Gastroenterology 1985;88:80–85.
Robrecht P, Deschodt-Lanckman M, Neff DEP, et al. Effect of somatostatin on pancreatic exocrine function: interaction with secretin. Biochem Biophys Res Commun 1975;67:315–23.
Alberti KGMM, Christensen SE, Iversen J, et al. Inhibition of insulin secretion by somatostatin. Lancet 1973;2:1299–301.
Hortnagl H, Singer EA, Lenz K. Substance P is markedly increased in plasma of patients with hepatic coma. Lancet 1984; 1:480–83.
Sieber C, Mosca G, Groszmann RJ. Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats. Am J Physiol 1992;262:G274-G277.
Pizcueta MP, Garcia-Pagan JC, Fernandez M, et al. Glucagon hinders the effects of somatostatin on portal hypertension. A study in rats with partial portal vein ligation. Gastroenterology 1991;101:1710–15.
Granger DN, Kvietys PR, Willborm WH, et al. Mechanism of glucagon-induced intestinal secretion. Am J Physiol 1980;239:G30-G38.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hori, N., Okanoue, T., Sawa, Y. et al. Effect of a somatostatin analogue (SMS 201–995) on hemodynamics and glucagon secretion in cirrhotic rats. Gastroenterol Jpn 28, 276–283 (1993). https://doi.org/10.1007/BF02779231
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02779231